Evaluating sustained adherence to ibrutinib in previously treated CLL - European Medical Journal

This site is intended for healthcare professionals

Evaluating sustained adherence to ibrutinib in previously treated CLL

Oncology
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of North Shore-LIJ Cancer Institute, Lake Success, NY, discusses the results of an analysis that evaluated the effect of a once-daily 420 mg dose of ibrutinib, a Bruton’s tyrosine kinase inhibitor, on progression-free survival in patients with previously treated chronic lymphocytic leukaemia (CLL) from the phase 3 RESONATE trial.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.